Drug Pricing Reform In US: It’s Over For 2017
Executive Summary
There's lots of buzz about drug pricing actions, be they executive or legislative. But the die is cast for this year: real reforms will have to wait.
You may also be interested in...
Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
340B Program Controls: House Committee Launches Investigation
Energy and Commerce Committee leadership requests audit records and other documents from the Health Resources and Services Administration to evaluate the effectiveness of its oversight of the program.